Citing three cases of non-fatal thrombotic (clotting) events, Novo Nordisk (NVO -5.2%) has suspended three
clinical trials evaluating concizumab for the prophylactic treatment of
hemophilia A & B patients regardless of inhibitor status.
Recruitment will cease as will treatment of patients already enrolled.
The company and the independent Data Monitoring
Committee are assessing the situation but no decisions on a path forward
have been made yet.
Concizumab is a subcutaneously administered
anti-tissue factor pathway-inhibiting monoclonal antibody that the
company says allows the body to generate adequate amounts of factor Xa
to ensure effective hemostasis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.